The Claim
Combination therapy using photodynamic therapy and anti-VEGF agents (ranibizumab or aflibercept) significantly improves best-corrected visual acuity by a mean difference of 0.07 logMAR units and reduces central subfield thickness by 42.09 micrometers in treatment-naïve patients with polypoidal choroidal vasculopathy compared to either monotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In treatment-naïve patients with polypoidal choroidal vasculopathy, combining photodynamic therapy with anti-VEGF drugs results in a measurable improvement in visual acuity and a reduction in retinal thickness compared to using either treatment alone.
See the scientific wording
Combination therapy using photodynamic therapy and anti-VEGF agents (ranibizumab or aflibercept) significantly improves best-corrected visual acuity by a mean difference of 0.07 logMAR units and reduces central subfield thickness by 42.09 micrometers in treatment-naïve patients with polypoidal choroidal vasculopathy, compared to either monotherapy, indicating superior anatomical and functional outcomes.
Light therapy closes off abnormal blood vessels in the eye, while the injection stops fluid from leaking out of blood vessels. Together, they remove excess fluid from the retina and allow the retina to function better, improving vision.
What the research says
1 studyFor people with this eye condition, combining two treatments—light therapy and eye injections—works better than using either one alone. It helps them see better and reduces fluid buildup in the retina more effectively.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.